GEN Exclusives

More »

GEN News Highlights

More »
Feb 4, 2008

Acorda Purchases Assets from Neurorecovery

  • Neurorecovery sold certain assets to Acorda Therapeutics in exchange for 100,000 shares of its common stock. Acorda’s stock was valued at $26.86 at close on Friday.

    Under the terms of the purchase deal, Acorda was assigned two licensing and research agreements relating to the use of aminopyridines in peripheral neuropathies and two early-stage development candidates. Acorda also acquired Neurorecovery’s preclinical and clinical data, regulatory filings, copyrights, trademarks, and domain names relating to three products.

    Acorda’s lead clinical product, Fampridine-SR, is also part of the aminopyridine family. It is in a Phase III trial to evaluate its safety and efficacy in improving walking ability in people with MS. Acorda believes that the assets gained from Neurorecovery will allow it to investigate other additional therapeutic indications for Fampridine-SR.

    The transaction will be accounted for as an acquisition of in-process R&D assets, according to Acorda. It will result in a noncash expense in the first quarter of approximately $2.7 million, the company adds.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »